LYCOS RETRIEVER 
Boehringer Ingelheim
built 656 days ago
Developed by Boehringer Ingelheim, in partnership with the RJO Group, the RLS Simulator is a virtual reality sensory encounter simulating the experiences of an RLS sufferer. Designed to help physicians better understand the symptoms and impact of RLS, the RLS Simulator allows them to experience – from a first-person point of view – a typical “day in the life” of an RLS sufferer, while feeling the uncomfortable leg sensations associated with RLS. The RLS Simulator utilizes an audio-video headset and state-of-the-art custom-made boot with an inflatable lining that tightens around the participants’ leg. It is intended to mimic RLS symptoms by stimulating leg and calf muscles and providing various sensory elements, like vibrations and temperature changes. The RLS Simulator is a pure simulation; that is, it does not induce restless legs syndrome symptoms or assist in a diagnosis; it merely simulates symptoms associated with RLS for educational purposes.
Source:
Boehringer Ingelheim (Canada) Ltd. would additionally like to take this opportunity to inform you that the VIRAMUNE® Product Monograph is being revised to provide updated safety information regarding the occurrence of serious skin rashes with VIRAMUNE® therapy. This strengthened information includes a reminder regarding the importance of the 14-day 200 mg lead-in period. It ... includes information from a clinical trial in which concomitant prednisone use was associated with an increase in the incidence and severity of rash during the first 6 weeks of VIRAMUNE® therapy. Therefore, use of prednisone to prevent VIRAMUNE®-associated rash is not recommended.
Source:
As of December 2005, the Boehringer Ingelheim group of companies had nearly 37,500 employees worldwide. Of these, around 30% worked in production, 37% in marketing and sales and 16% in research and development. In Germany, Belgium, Brazil, the Netherlands, Switzerland and the United Kingdom, Boehringer Ingelheim has received recognition as one of the best employers. For example, the German magazine 'Capital' placed the company second in a 2005 list of Germany's best employers, and in the United Kingdom the company was placed 19th in The Sunday Times' 100 Best Companies To Work For. In 2006 the Science magazine (US) put Boehringer Ingelheim at the 2nd place of the top employers in the biotechnology and pharmaceutical industries.[1].
Source:
On top of that Boehringer Ingelheim decided to introduce a new, considerably lower preferential price for original Viramune of 0.60 US Dollars. This means that in all African countries and all other low-income countries as per World Bank classification, some 78 countries, the daily treatment costs for Viramune will be cut on an average in half compared to the former preferential price. This former preferential price of 1.20 US Dollars will now be extended additionally to 67 middle income countries, such as some South and Central American and Eastern European countries not belonging to the above mentioned group. This price is a more than 90 percent discount on the price for the treatment in highly industrialized countries.
Source:
Boehringer Ingelheim (BI) launched Phase III RESIST clinical trials to study the efficacy and safety of tipranavir for use in combination therapy for HIV infection. Tipranavir is the first non-peptidic protease inhibitor (NPPI) in development for the treatment of HIV infection. The RESIST trials will evaluate triple-class-experienced patients in more than 280 clinical trial sites worldwide. PRNewswire, 2/6/03
Source:
Boehringer Ingelheim is committed to the research and development of novel antiretroviral agents. VIRAMUNE (nevirapine) is a product of original research done at Boehringer Ingelheim. VIRAMUNE was the first member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV drugs. Boehringer Ingelheim is committed to the rapid development of the investigational non-peptidic protease inhibitor tipranavir. The company is involved in basic research and is committed to improving HIV therapy by providing physicians and patients with innovative antiretrovirals.
Source:
MORE ABOUT
Boehringer Ingelheim